Quantcast

 FSD Pharma to Establish Presence in Canada’s Insurance Regimes

Signs agreement focusing on exploring insurance coverage for
medical cannabis Canada wide

TORONTO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/FSDDF?src=hash" target="_blank"gt;#FSDDFlt;/agt;–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the
“Company”), announced today the signing of a consulting agreement with
Joseph L. Romano, a well-respected lawyer with a strong track-record in
personal injury law. Mr. Romano has been working with medical cannabis
since 2006, assisting people coping with chronic pain to have access to
medical cannabis, a viable alternative to opioid based medications.

Pursuant to the terms of the agreement, Mr. Romano will provide
consulting on the inner workings of third party actions, WSIB claim
handling, first party coverage and no fault benefits across Canada. Mr.
Romano will also assist in identifying strategic acquisitions that will
enhance shareholder value.

Commenting on the agreement, Dr. Raza Bokhari, Executive Co-Chairman and
interim CEO said, “We are very excited to engage Mr. Romano in advance
of our anticipated sales license. This is a very timely and important
agreement for FSD Pharma to maximize the opportunities in the Canadian
market for our products and fits well with our strategy of establishing
the company as a leader in medical cannabis.”

In consideration for his services, FSD will pay Mr. Romano consulting
fees, warrants and shares in the company, subject to compliance with all
applicable securities laws and the policies of the Canadian Securities
Exchange.

About FSD Pharma

FSD Pharma is focused on the development of the highest quality indoor
grown, pharmaceutical grade cannabis and on the research and development
of novel cannabinoid-based treatments for several central nervous system
disorders, including chronic pain, fibromyalgia and irritable bowel
syndrome. The Company has 25,000 square feet available for production at
its Ontario facility with an additional 220,000 square feet currently in
development (with an estimated cost of $250 per square foot to be
completed in 2019).

FSD facilities sit on 72 acres of land with 40 acres primed for
development and an expansion capability of up to 3,896,000 square feet.

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under
the Cannabis Act and Regulations, having received its cultivation
license on October 13, 2017. FV Pharma’s vision is to transform its
current headquarters in a Kraft plant in Cobourg, Ontario into the
largest hydroponic indoor grow facility in the world. FV Pharma intends
to cover all aspects of this exciting new industry, including
cultivation, legal, processing, manufacturing, extracts and research and
development.

Forward-Looking Information

Neither the CSE nor its Market Regulator (as that term is defined in
the policies of the CSE) accepts responsibility for the adequacy or
accuracy of this release.

Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance. The use of any of the words “could”,
“intend”, “expect”, “believe”, “will”, “projected”, “estimated” and
similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information
and are based on FSD Pharma’s current belief or assumptions as to the
outcome and timing of such future events. Actual future results may
differ materially. Actual results and developments may differ materially
from those contemplated by these. The forward-looking information
contained in this press release is made as of the date hereof, and FSD
Pharma is not obligated to update or revise any forward-looking
information, whether as a result of new information, future events or
otherwise, except as required by applicable securities laws. Because of
the risks, uncertainties and assumptions contained herein, investors
should not place undue reliance on forward looking-information. The
foregoing statements expressly qualify any forward-looking information
contained herein.

Contacts

Zeeshan Saeed, President, Founder and Director, FSD Pharma Inc., Email: [email protected],
Telephone: (416) 854-8884

Investor Relations: Email: [email protected],
Website: www.fsdpharma.com

Media Relations: Nic Johnson, Email: [email protected],
Tel: (212) 845-4242

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.